Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):972; doi:10.1093/jnci/93.13.972
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 972, July 4, 2001
© 2001 Oxford University Press

NEWS

After 30 Years of Laboratory Work, a Quick Approval for STI571

Katherine Arnold

STI571 was first tested in humans in June 1998. Its approval as GleevecTM came just under 3 years later on May 10, 2001, after the U.S. Food and Drug Administration completed its review of the new drug application in a mere 2 1/2 months. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Cataldi, A. Gaudino, V. Lariccia, M. Russo, S. Amoroso, G. di Renzo, and L. Annunziato
Imatinib-Mesylate Blocks Recombinant T-Type Calcium Channels Expressed in Human Embryonic Kidney-293 Cells by a Protein Tyrosine Kinase-Independent Mechanism
J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 208 - 215.
[Abstract] [Full Text]